SG11201806620TA - Compositions and methods for treating infections - Google Patents
Compositions and methods for treating infectionsInfo
- Publication number
- SG11201806620TA SG11201806620TA SG11201806620TA SG11201806620TA SG11201806620TA SG 11201806620T A SG11201806620T A SG 11201806620TA SG 11201806620T A SG11201806620T A SG 11201806620TA SG 11201806620T A SG11201806620T A SG 11201806620TA SG 11201806620T A SG11201806620T A SG 11201806620TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- co7d
- pct
- new york
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291900P | 2016-02-05 | 2016-02-05 | |
| US201662375712P | 2016-08-16 | 2016-08-16 | |
| PCT/US2017/016224 WO2017136556A1 (fr) | 2016-02-05 | 2017-02-02 | Compositions et méthodes de traitement d'infections bactériennes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806620TA true SG11201806620TA (en) | 2018-09-27 |
Family
ID=59500993
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806620TA SG11201806620TA (en) | 2016-02-05 | 2017-02-02 | Compositions and methods for treating infections |
| SG10202007239QA SG10202007239QA (en) | 2016-02-05 | 2017-02-02 | Compositions and methods for treating infections |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202007239QA SG10202007239QA (en) | 2016-02-05 | 2017-02-02 | Compositions and methods for treating infections |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10774073B2 (fr) |
| EP (1) | EP3411367A4 (fr) |
| JP (1) | JP6949055B2 (fr) |
| KR (1) | KR20180119590A (fr) |
| CN (1) | CN109071486A (fr) |
| AU (2) | AU2017213824B9 (fr) |
| BR (1) | BR112018015924A2 (fr) |
| CA (1) | CA3013760A1 (fr) |
| CL (1) | CL2018002074A1 (fr) |
| CU (1) | CU20180083A7 (fr) |
| EA (1) | EA201891766A1 (fr) |
| IL (2) | IL260952B (fr) |
| MX (1) | MX2018009504A (fr) |
| PH (1) | PH12018501646A1 (fr) |
| SG (2) | SG11201806620TA (fr) |
| TW (1) | TW201731836A (fr) |
| WO (1) | WO2017136556A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6949055B2 (ja) | 2016-02-05 | 2021-10-13 | ヴェラ ファーマシューティカルズ，エルエルシー | 感染症を治療するための組成物および方法 |
| AU2018312985A1 (en) * | 2017-08-07 | 2020-02-27 | Vyera Pharmaceuticals, LLC | DHFR inhibitors, compositions, and methods related thereto |
| EP3795684A4 (fr) | 2018-04-26 | 2022-01-05 | Guangzhou Cas Lamvac Biotech Co., Ltd. | Système d'atténuation et utilisation associée |
| JP2023539463A (ja) | 2020-08-17 | 2023-09-14 | アリゴス セラピューティクス インコーポレイテッド | Ｐｄ－ｌ１を標的とするための方法及び組成物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4532240A (en) | 1982-09-09 | 1985-07-30 | Warner-Lambert Company | Diaminopyrimidines |
| CA1244028A (fr) | 1983-04-14 | 1988-11-01 | Hans Maag | Derives de pyrimidine |
| AU4690999A (en) * | 1998-08-13 | 2000-03-06 | Warner-Lambert Company | Diaminopyrimidines and combination therapies effective for treatment of p-glycoprotein positive cancers |
| US20040006042A1 (en) * | 1998-08-13 | 2004-01-08 | Berry David Allen | Diaminopyrimidines and combination therapies effective for treatment of P-glycoprotein positive cancers |
| JP6949055B2 (ja) * | 2016-02-05 | 2021-10-13 | ヴェラ ファーマシューティカルズ，エルエルシー | 感染症を治療するための組成物および方法 |
| AU2018312985A1 (en) | 2017-08-07 | 2020-02-27 | Vyera Pharmaceuticals, LLC | DHFR inhibitors, compositions, and methods related thereto |
-
2017
- 2017-02-02 JP JP2018560444A patent/JP6949055B2/ja active Active
- 2017-02-02 SG SG11201806620TA patent/SG11201806620TA/en unknown
- 2017-02-02 CU CU2018000083A patent/CU20180083A7/es unknown
- 2017-02-02 CN CN201780021371.XA patent/CN109071486A/zh active Pending
- 2017-02-02 MX MX2018009504A patent/MX2018009504A/es unknown
- 2017-02-02 US US16/075,924 patent/US10774073B2/en active Active
- 2017-02-02 KR KR1020187025469A patent/KR20180119590A/ko not_active Application Discontinuation
- 2017-02-02 AU AU2017213824A patent/AU2017213824B9/en active Active
- 2017-02-02 EP EP17748159.5A patent/EP3411367A4/fr active Pending
- 2017-02-02 WO PCT/US2017/016224 patent/WO2017136556A1/fr active Application Filing
- 2017-02-02 SG SG10202007239QA patent/SG10202007239QA/en unknown
- 2017-02-02 BR BR112018015924A patent/BR112018015924A2/pt active Search and Examination
- 2017-02-02 EA EA201891766A patent/EA201891766A1/ru unknown
- 2017-02-02 CA CA3013760A patent/CA3013760A1/fr active Pending
- 2017-02-03 TW TW106103740A patent/TW201731836A/zh unknown
-
2018
- 2018-08-02 CL CL2018002074A patent/CL2018002074A1/es unknown
- 2018-08-02 IL IL260952A patent/IL260952B/en unknown
- 2018-08-02 PH PH12018501646A patent/PH12018501646A1/en unknown
-
2020
- 2020-09-10 US US17/016,702 patent/US11530198B2/en active Active
-
2022
- 2022-02-14 AU AU2022200967A patent/AU2022200967A1/en not_active Abandoned
- 2022-03-10 IL IL291266A patent/IL291266A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018015924A2 (pt) | 2018-12-26 |
| SG10202007239QA (en) | 2020-09-29 |
| WO2017136556A1 (fr) | 2017-08-10 |
| CU20180083A7 (es) | 2019-03-04 |
| CN109071486A (zh) | 2018-12-21 |
| TW201731836A (zh) | 2017-09-16 |
| AU2017213824B9 (en) | 2021-11-25 |
| EP3411367A4 (fr) | 2019-07-10 |
| EP3411367A1 (fr) | 2018-12-12 |
| KR20180119590A (ko) | 2018-11-02 |
| MX2018009504A (es) | 2019-05-06 |
| US10774073B2 (en) | 2020-09-15 |
| IL291266A (en) | 2022-05-01 |
| CL2018002074A1 (es) | 2019-02-01 |
| IL260952B (en) | 2022-04-01 |
| AU2017213824B2 (en) | 2021-11-18 |
| JP6949055B2 (ja) | 2021-10-13 |
| EA201891766A1 (ru) | 2019-02-28 |
| AU2022200967A1 (en) | 2022-03-03 |
| US20190077794A1 (en) | 2019-03-14 |
| US11530198B2 (en) | 2022-12-20 |
| PH12018501646A1 (en) | 2019-05-27 |
| CA3013760A1 (fr) | 2017-08-10 |
| AU2017213824A1 (en) | 2018-09-06 |
| JP2019504889A (ja) | 2019-02-21 |
| US20200407345A1 (en) | 2020-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201906883SA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201806620TA (en) | Compositions and methods for treating infections | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201909501TA (en) | Personalized 3d neural culture system for generating human oligodendrocytes and studying myelination in vitro | |
| SG11201408171SA (en) | Fbxo3 inhibitors | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201900123TA (en) | Compositions and methods for treating frontotemporal dementia |